



Macro Insights Weekly A health-check on India

Group Research February 26, 2024



Taimur BaigChief Economist
taimurbaig@dbs.com



Nathan Chow Senior Economist nathanchow@dbs.com

For Alliance Bank clients, please direct your enquiries to Malaysia Research +603 2604 3915 general@alliancedbs.com

- India is in multiple sweet spots, from geo-strategic to demographics. 5.5.-6.5% growth looks par for the course. But what would it take for growth to head toward 7%?
- The economy has weathered two major shocks—the 2020/21 pandemic and the 2022 food/energy shock.
- Yet, business and consumer sentiments have revived, demand markers are robust, and BOP is stable.
- Three areas need momentum for growth to head toward 7%. First, literacy and skills need enhancing.
- Second, health indicators are lagging peers; more investment would help productivity.
- Third, openness to trade and regional cooperation by embracing regional value chains is key.

Key data release and events this week:

- South Korea exports are projected to decelerate with during the LNY festival.
- We forecast a subdued growth report for India for 4Q23.
- Singapore industrial production is expected to rebound and return to expansion.

Chart of the Week: Expensive stocks

Exuberance around artificial intelligence and a resilient demand environment have pushed US stock markets to a series of record highs. Going by valuation metrics like yield gap, US stocks look rather expensive, around the same level as they were prior to the 2007-08 global financial crisis. Short of a major economic or financial sector shock, it is hard to see the current state of investor confidence getting dented. We are tracking interest rate sensitive parts of the economy, especially as continued market rally could get in the way of Fed rate cuts.

10Y UST yield - SP500 Dividend yield




Commentary: A health-check on India


India is in multiple sweet spots. From geostrategic to demographics, there are plenty of well-discussed motivating factors for global investors to look at India favourably. Domestic infrastructure, both physical and electronic, has improved considerably, social welfare has expanded, consumer confidence has risen, and asset markets are buoyant. External balances, long susceptible to volatile investment flows and global energy shocks, are beginning to turn for the better as services surplus offsets most of the trade deficit.

All of this is remarkable given that India has faced two major shocks since 2020. First was the economic contraction during the Covid pandemic, while the second was the food/energy terms of trade shocks after Russia's invasion of Ukraine. At currently projected growth rates, it will only be in 2026 that India makes up the ground lost during the pandemic, illustrating the magnitude of the shock. Meanwhile, buying crude oil from Russia and exporting some of it in refined form was a shock absorber in 2022-23.

Recovery and prospects



Looking at the 2024 outlook, although inflation remains under RBI's scrutiny, the economy seems to be doing just fine without additional monetary or fiscal easing. Looking at demand markers both at urban and rural areas, real GDP growth of 5.5-6.5% is par for the course now.



Source: CEIC, calculations by DBS (set of proxy variables)

What would it take for growth to head toward 7% on a sustainable basis? We see three key drivers, health, education, and trade. Some improvement notwithstanding, there is considerable room for improving literacy, technical skills, women's role in the labour force, and public health. On human capital and health indicators, India lags in many of its peers. To embrace large scale manufacturing, progress in these areas is a must.

India also needs to reduce tariff and nontariff barriers to trade and make progress toward to becoming embedded in the regional supply and value chains. No economy is large enough to do it alone in this world of complex production processes. Regional cooperation and openness to trade will provide India with the kind of high return endeavours critically needed for the prosperity the nation aspires.

Taimur Baig

Key forecasts for the week

Event	DBS	Previous
Feb 26 (Mon)		
Singapore: industrial production (Jan)	4.2% y/y	-2.5% y/y
Feb 27 (Tue)		
Hong Kong: exports (Jan)	15.3% y/y	11.0% y/y
- imports	16.2% y/y	11.6% y/y
- trade balance	-HKD26.6bn	-HKD59.9bn
Japan: CPI (Jan)	1.8% y/y	2.6% y/y
Taiwan: export orders (Jan)	-10% y/y	-16.0% y/y
Feb 29 (Thu)		
Taiwan: industrial production (Jan)	0.5% y/y	-4.0% v/v
India: GDP (4Q)	6.8% y/y	7.6% y/y
Vietnam: exports (Feb)	11.0% y/y	42.0% y/y
- imports	12.5% y/y	33.3% y/y
- trade balance	USD2.2bn	USD2.9bn
 Retail sales YoY YTD 	9.0% y/y	8.1% y/y
- CPI	3.5% y/y	3.4% y/y
Mar 1 (Fri)		
Hong Kong: retail sales value (Jan)	7.5% y/y	7.8% y/y
South Korea: exports (Feb)	1.0% y/y	18.1% y/y
- imports	-13.6% y/y	-7.8% y/y
- trade balance	USD2.7bn	USD0.3bn
Indonesia: CPI (Feb)	2.5% y/y	2.6% y/y

Central bank policy meetings

Reserve Bank of New Zealand (28 Feb): Look for the RBNZ to keep the official cash rate unchanged at 5.50% for the fifth meeting. RBNZ Governor Adrian Orr joined the Fed and other central banks against pivoting towards an interest rate cut anytime soon. According to an RBNZ Survey in 1Q24, the median 2-year inflation expectations of households increased to 3.2% from 3% in the previous quarterly survey, slightly above the 1-3% inflation target. However, interest rate futures have gotten ahead of themselves, expecting a slight chance of a hike in the coming meetings. The NZ economy is fragile compared to its peers. The seasonally adjusted real GDP contracted QoQ in three of the four quarters through 3Q23. The final quarter of 2023 does not look promising. Retail sales ex inflation shrank by 1.9% QoQ sa in 4Q23, worse than the 0.8% decline a quarter earlier. The unemployment rate increased for a second year to 4% in 2023 from 3.4% in 2022. On balance, the RBNZ's next move will likely be a rate cut than a hike.

Forthcoming data releases

Japan: CPI inflation is expected to decelerate to 1.8% YoY in January from the 2.6% recorded in Dec23. Excluding fresh food and energy, inflation is projected to persist above the 2% threshold, reaching 3.2% in January. In light of the moderation in inflation data and the weakness in 4Q23 GDP, the likelihood of an early termination of the negative interest rate policy at the March BOJ meeting has decreased substantially. The possibility of such a move in April remains viable, given the ongoing increase in corporate profits and the potential for wage hikes during the Shunto negotiations.

South Korea: Exports are projected to decelerate to 1% YoY in February from the notable 18% growth observed in January, primarily due to the reduced number of working days attributed to the Lunar New Year festival. Nevertheless, the overall export growth for the initial two months of this year is expected to average 9.5%, surpassing the 5.7% recorded in 4Q23. With the concurrent decrease in inventories and the rebound in manufacturing PMI (51.2 in January), there is a strong likelihood that industrial output will experience a significant pickup in 1Q.

Taiwan: Export orders are expected to show some improvement, reaching -10% YoY in January, following a decline of -16% in Dec23. Industrial production is expected to experience a slight uptick, reaching 0.5% in January as opposed to the -4% recorded in Dec23. The gradual increase in semiconductor demand and gradual digestion of excess inventories continue to contribute to the outlook for a Ushaped growth recovery.

Hong Kong SAR: Retail sales growth is expected to moderate from 7.8% YoY in Dec to 7.5% YoY in Jan. Hong Kong saw 7.5 million local resident departures in Jan, equivalent to 51% of the total visitor arrivals. This ratio exceeded the 2023 monthly average of 46%. The robust HKD is constraining the spending capacity of tourists and encouraging local residents to travel. Weakened asset markets are also adversely affecting consumer confidence, creating a negative wealth effect. The value of total exports of goods is projected to increase from 11.0% YoY to 15.3% YoY, while simultaneously. the value of imports of goods decreased by 16.2% YoY. The low base effect largely contributes to such improvement. External demand from Mainland China and the rest of the world continues to face challenges due to high interest rates.

Singapore: We expect Singapore's industrial production to rebound and return to expansion of 4.2% YoY in January 2024, after decelerating in 2023's final two months. Part of the upside was due to favourable base effect, with January 2023's print falling by 2.9% YoY, as it coincided with the Lunar New Year. January 2024's improvement was possibly driven by electronics, precision engineering, and chemicals.

Vietnam: Vietnam's exports growth likely normalised to 11.0% YoY in February 2024, after January's surge of 42.0% YoY, due to the Tết holidays. Despite the volatility, the continued expansion remains in line with our expectations for better exports performance in 2024 vs 2023, amid a turnaround in the global electronics cycle. We expect faster retail sales growth in February 2024, due to seasonal impact from the holidays. In our view, headline inflation was likely 3.5% YoY in February 2024, hovering near the 3.4% YoY to 3.6% YoY range since October 2023. Food and transport inflation remained contained, even though administered health price increases have guickened due to upward adjustments since November 2023 to align nationwide prices.

Economics Team

FX: No clear sign that DXY will keep falling or EUR and NZD will keep rising

The **DXY Index retreated to 104** last week **after failing to break above 105** on 13-14 February. The Fed has successfully pushed back the market's aggressive rate cut bets for 2024. As of last Friday, interest rate futures discounted 3-4 cuts this year, fewer than the 7 reductions in December. They also see the Fed delivering its first cut in June instead of March.





Sources: DBS Research, Bloomberg data

However, last Thursday, DXY bounced off 103.4, the floor of a price channel. Fed officials are determined that the market does not deviate from the 3 cuts projected in December's dot plot. They have also rallied around Fed Chair Jerome Powell's guidance that a rate cut was not the base scenario at the next FOMC meeting on 20 March. At his semiannual congressional testimonies on 6-7 March, Powell will likely warn that excessive easing amid a resilient US economy could lead to a stalling or reversal in the progress achieved so far to restore price stability. On 29 February, look for the PCE deflators to mirror the surprises in CPI. Consensus sees headline inflation rising to 0.3% MoM in January from 0.2% in December and core inflation to 0.4% from 0.2%. With initial jobless claims declining

a third week to 201k for the 17 February week, those looking for nonfarm payrolls (on 8 March) to fall below 200k in February may be disappointed again.

EUR/USD rose into a higher 1.08-1.09 range last week vs. 1.07-1.08 the previous fortnight. This week, a fall in the Eurozone's CPI inflation will not lead the European Central Bank to lower rates at next week's governing council meeting. Today, ECB President Christine Lagarde will tell the EU Parliament that the spring wage negotiations need to affirm the sustainability of disinflation for an interest rate cut this summer. However, EUR/USD could slip below 1.08 again. Interest rate futures see the ECB lowering rates by the same 75-100 bps as the Fed this year. The risks could tilt in the USD's favour if the CPI estimate on 1 March affirms the ECB's expectation to reach the 2% target by summer or autumn. Consensus expects headline inflation to slow to 2.5% YoY in February from 2.8% in January and core inflation to 2.9% from 3.3%.

NZD/USD's rise to 0.62 last week is as tenuous as the fragile New Zealand economy. With inflation expectations above the 1-3% target, we expect inflation the Reserve Bank of New Zealand to keep rates unchanged at 5.50% on 28 February. However, interest rate futures have gotten ahead of themselves in their mild bets for a hike at the April or May meetings. After contracting QoQ sa in three of the four quarters through 3Q23, real GDP looks weak in 4Q23. Apart from retail sales ex inflation contracting by a deeper 1.9% QoQ sa in 4Q23 vs. the 0.8% decline in 3Q23, the jobless rate increased to 4% in 4Q23 for the first time since 2Q21. Despite its concern about high rates weighing on the economy, the Treasury Department hinted at spending cuts in the May budget announcement.

Philip Wee

Group Research

Economics & Strategy

Taimur BAIG, Ph.D.
Chief Economist

Global

taimurbaig@dbs.com

Wei Liang CHANG

FX & Credit Strategist Global

weiliangchang@dbs.com

Nathan CHOW

Senior Economist China/HK SAR nathanchow@dbs.com

Han Teng CHUA, CFA

Economist Asean

hantengchua@dbs.com

Mo JI, Ph.D.

Chief Economist
China/HK SAR
mojim@dbs.com

Byron Lam

Economist
Hong Kong
byronlamfc@dbs.com

Violet LEE

Associate Publications violetleeyh@dbs.com

Tracy Li Jun Lim

Credit Analyst
USD Credit
tracylimt@dbs.com

Eugene LEOW

Senior Rates Strategist G3 & Asia eugeneleow@dbs.com

Teng Chong LIM

Credit Analyst
SGD Credit
tengchonglim@dbs.com

Tieving MA, CFA

Senior Economist
Japan, South Korea, Taiwan
matieving@dbs.com

Radhika RAO

Senior Economist
Eurozone, India, Indonesia
radhikarao@dbs.com

Amanda SEAH

Credit Analyst
SGD Credit

amandaseah@dbs.com

Daisy SHARMA

Analyst
Data Analytics
daisy@dbs.com

Joel SIEW, CFA

Credit Analyst SGD Credit joelsiew@dbs.com

Mervyn TEO

Credit Strategist
USD Credit
mervynteo@dbs.com

Samuel TSE

Economist
China/HK SAR
samueltse@dbs.com

Philip WEE

Senior FX Strategist Global philipwee@dbs.com **Sources**: Data for all charts and tables are from CEIC, Bloomberg and DBS Group Research (forecasts and transformations)

GENERAL DISCLOSURE/ DISCLAIMER (For Macroeconomics, Currencies, Interest Rates)

The information herein is published by DBS Bank Ltd and/or DBS Bank (Hong Kong) Limited and distributed by AllianceDBS Research Sdn Bhd (ADBS), a subsidiary of Alliance Bank Malaysia Berhad (ABMB) (each and/or collectively, the "Company"). It is based on information obtained from sources believed to be reliable, but the Company does not make any representation or warranty, express or implied, as to its accuracy, completeness, timeliness or correctness for any particular purpose. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained herein does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. The information herein is published for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate legal or financial advice. The Company, or any of its related companies or any individuals connected with the group accepts no liability for any direct, special, indirect, consequential, incidental damages or any other loss or damages of any kind arising from any use of the information herein (including any error, omission or misstatement herein, negligent or otherwise) or further communication thereof, even if the Company or any other person has been advised of the possibility thereof. The information herein is not to be construed as an offer or a solicitation of an offer to buy or sell any securities, futures, options or other financial instruments or to provide any investment advice or services. The Company and its associates, their directors, officers and/or employees may have positions or other interests in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking or financial services for these companies. The information herein is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction (including but not limited to citizens or residents of the United States of America) where such distribution, publication, availability or use would be contrary to law or regulation. The information is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction (including but not limited to the United States of America) where such an offer or solicitation would be contrary to law or regulation.

This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) which is Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 65-6878-8888 for matters arising from, or in connection with the report. This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd.

DBS Bank Ltd., 12 Marina Boulevard, Marina Bay Financial Centre Tower 3, Singapore 018982. Tel: 65-6878-8888. Company Registration No. 196800306E.

DBS Bank Ltd., Hong Kong Branch, a company incorporated in Singapore with limited liability. 18th Floor, The Center, 99 Queen's Road Central, Central, Hong Kong SAR.

DBS Bank (Hong Kong) Limited, a company incorporated in Hong Kong with limited liability. 13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong SAR

AllianceDBS Research Sdn Bhd (128540 U), 19th Floor, Menara Multi-Purpose, Capital Square, 8 Jalan Munshi Abdullah, 50100 Kuala Lumpur, Malaysia. Tel.: +603 2604 3915.

Virtual currencies are highly speculative digital "virtual commodities", and are not currencies. It is not a financial product approved by the Taiwan Financial Supervisory Commission, and the safeguards of the existing investor protection regime does not apply. The prices of virtual currencies may fluctuate greatly, and the investment risk is high. Before engaging in such transactions, the investor should carefully assess the risks, and seek its own independent advice.